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The NFB transcription factor is a key component of im-
mune and inflammatory signaling as its activation induces the
expression of antimicrobial reagents, chemokines, cytokines,
and anti-apoptotic factors. Many pathogens encode effector
proteins that target factors regulating NFB activity and can
provide novel insights on regulatory mechanisms. Given the
link of NFB dysfunction with inflammatory diseases and
some cancers, these effectors have therapeutic potential. Here,
screening enteropathogenic Escherichia coli proteins for those
implicated in suppressing NFB function revealed that eGFP-
NleC, unlike eGFP, strongly inhibited basal and TNF-in-
duced NFB reporter activity to prevent secretion of the che-
mokine, IL-8. Work involving NleC variants, chemical
inhibitors, and immunoprecipitation studies support NleC
being a zinc metalloprotease that degrades NFB-IB com-
plexes. The findings are consistent with features between resi-
dues 33–65 recruiting NFB for proteasomal-independent
degradation by a mechanism inhibited by metalloprotease in-
hibitors or disruption of a consensus zinc metalloprotease mo-
tif spanning NleC residues 183–187. This raises the prospect
that mammalian cells, or other pathogens, employ a similar
mechanism to modulate NFB activity. Moreover, NleC repre-
sents a novel tool for validating NFB as a therapeutic target
and, indeed, as a possible therapeutic reagent.
Interaction of inflammatory stimuli, such as cytokines and
microbial products, with their cognate receptors induces
ubiquitination and phosphorylation cascades that alter the
transcriptional profile of the cell to produce factors including
antimicrobials, chemokines (e.g. IL-8), and cytokines (e.g.
TNF; see Refs. 1–4). A critical player in this process is the
transcription factor nuclear factor B (NFB),3 which forms
homo- or heterodimers composed of p65 (RelA), RelB, c-Rel,
p50, and p52 proteins, with the p65/p50 dimer being the most
abundant and associated with the canonical NFB pathway.
The p65/p50 dimer is retained within the cytoplasm bound
to the inhibitor of B (IB) until receptor-mediated activation
of the inhibitor of B kinase (IKK) phosphorylates IB,
thereby triggering its proteasomal degradation to release
NFB for import into the nucleus. Signaling by many recep-
tors converges at the IKK complex, composed of IKK, IKK,
and the NFB essential modulator (IKK), but often involves
distinct or overlapping upstream adaptors including TRAF
and MyD88 and serine/threonine kinases such as IRAK, TGF-
-activated kinase 1, and RIP1 (1–4). The classic mechanism
to terminate NFB transcriptional activity involves the NFB-
dependent transactivation of IB, which shuttles the tran-
scription factor back into the cytoplasm (5, 6). However, addi-
tional regulatory mechanisms have been described including
proteasome-dependent degradation (7) or processing of p65
by caspase and serine proteases to generate forms with inhibi-
tory functions (8, 9). The importance of NFB in immune and
inflammatory signaling is reflected by the fact that its dys-
regulation is linked to many diseases including cancer, diar-
rhea, arthritis, inflammatory bowel disease, and neurodegen-
erative diseases (10, 11).
Given the co-evolution of micro-organisms with mammals,
it is not surprising that many, mostly pathogens, inhibit NFB
signaling as part of their strategy to colonize normally privi-
leged niches. Collectively, bacteria and viruses possess “effec-
tor” proteins that target most of the proteins known to play
roles in transmitting signals that report the presence of for-
eign antigens (12–14). Examples of how pathogens inhibit
NFB signaling at diverse levels include the A52R protein of
the vaccinia virus that acts as a dominant-negative homologue
of MyD88 (15), the Yersinia YopP/J protein whose acetylation
of IKK prevents activation (16, 17) and the ShigellaOspG
protein, which prevents IB ubiquitination by targeting an E2
ubiquitin-conjugating enzyme (18). Another bacterium, en-
teropathogenic Escherichia coli (EPEC), has recently been
reported to deliver at least three effectors into host cells to
inhibit NFB function. Although two of these effectors, NleB
and NleE, are speculated to block signaling at the level of
TGF--activated kinase 1 or IKK kinases (19, 20), the NleH
protein binds the NFB cofactor RPS3 (ribosomal protein S3)
to inhibit the transcription of a subset of genes (21). In this
study, we describe that the EPEC gene nleC encodes a protein
which targets p65, p50, and IB proteins for degradation by
a proteasome-independent mechanism. The findings suggest
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that NleC is a zinc metalloprotease that recruits NFB com-
plexes for degradation.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—HeLa cells (ATCC CCL-2)
were maintained at 37 °C in DMEM (Invitrogen) supple-
mented with 10% fetal calf serum in a 5% CO2 environment.
Hela cells seeded in 12- or 24-well plates (Nunc) were grown
for 24 h (to80% confluence) prior to introducing mamma-
lian expression vectors by transfection using jetPRIME
(PEQLAB Ltd.) following the manufacturer’s recommenda-
tions. Transfection efficiency was routinely60–80% (data
not shown). When required, the proteasomal inhibitor
MG132 (Calbiochem; final concentration, 25 M), NFB acti-
vation inhibitor (Calbiochem product no. 481406; final con-
centration, 0.28 M), protease inhibitor mixture (Sigma-
Aldrich, P8340 1/1000), GM6001 (final concentration, 25
M), or EDTA (final concentration, 2.5 mM) were added to
the medium just prior to transfection.
Plasmids—nleC gene constructs, including substitution and
truncation variants thereof, were all generated by PCR and
cloned into pEGFP-C1 (Clontech) using EcoRI/PstI restric-
tion sites, with desired gene product confirmed by DNA se-
quencing (GATC Biotech). Studies included plasmids encod-
ing the NFB luciferase reporter protein (22) and IKK
pathway components TRAF2, IKK, IKK (23, 24), and p65
(kindly provided by professor Neil D. Perkins, Newcastle
University).
Luciferase and IL-8 Assays—Approximately 24 h post-
transfection, HeLa cells were either left untreated or treated
with TNF (final concentration, 50 ng/ml) for 30 min prior to
addition of luciferase cell culture lysis buffer (Stratagene) fol-
lowing the manufacturer’s protocol. Luciferase levels were
measured using a FLUOstar Optima 413-3266 (BMG
Labtech) plate reader with 96-well plates containing 100 l
luciferase assay solution (Promega) and 25 l lysate per well.
By contrast, IL-8 levels in HeLa supernatants were deter-
mined using the OptEIATM Human IL-8 ELISA (BD Bio-
sciences) kit following the manufacturer’s recommendations.
These assays were routinely carried out48 h post-transfec-
tion with or without an additional 3-h incubation with TNF
(final concentration, 50 ng/ml).
Co-immunoprecipitation—For co-immunoprecipitation,
cells were transfected with plasmids encoding eGFP or eGFP-
fusion proteins as described above. The cells were lysed under
native conditions, and proteins were immunoprecipitated
using GFP-Trap beads (Chromotek) according to the manu-
facturer’s recommendations.
Western Blot Analyses—Cells were either lysed using 1
SDS sample buffer or in PBS with 1% Triton and protease in-
hibitors for subsequent fractionation as described previously
(25). Samples were equalized for protein content, separated
via SDS-PAGE (10–12%), and transferred onto nitrocellulose
membrane. Membranes were blocked in 5% skimmed milk
powder in Tris-buffered saline, pH 7.5, containing 0.1%
Tween (TBST) for 1 h followed by an overnight incubation at
4 °C in 5% BSA/TBST solution containing the appropriate
antibody. Membranes were washed and incubated in 5% skim
milk/TBST containing the respective HRP-conjugated sec-
ondary antibody (Jackson ImmunoResearch Laboratories).
Blots were developed in SuperSignal West Pico chemilumi-
nescent substrate (Pierce) according to the manufacturer’s
recommendations, and the signals were detected on Hyper-
film ECL (Amersham Biosciences). Primary antibodies used
were NFB p65, NFB p50, IB, IKK/ (Santa Cruz Bio-
technology), p65, phospho-p65 (Cell Signaling Technologies),
actin (Sigma), and GFP (Zymed Laboratories Inc.).
RESULTS
NleC Effector Inhibits NFB Reporter Activity and IL-8
Secretion—Bioinformatic analyses of the EPEC genome iden-
tified 21 putative effector genes (26, 27), of which one or more
are predicted to inhibit NFB function (25). Our previous
work argued against critical roles for the Tir, Map, EspF-H,
EspZ, EspG2, NleA, NleF, and NleH effectors (25), so other
effector-encoding genes were cloned into mammalian expres-
sion vectors for screening. NFB assays involved co-transfec-
tion studies using empty control plasmid (pEGFP-C1) and a
vector encoding the luciferase protein under the transcrip-
tional control of NFB (via a 5  promoter). This analysis
revealed basal levels of NFB activity in HeLa cells mediated
by multiple signaling pathways, as the “NFB activation inhib-
itor” (Calbiochem; product no. 481406) reduced luciferase
levels by only60% (Fig. 1A). Co-transfection studies con-
firmed basal NFB activity in pEGFP-transfected cells, with a
dramatic reduction (75%) in cells transfected with the
eGFP-NleC-expressing plasmid (Fig. 1B). Western blot analy-
sis revealed similar eGFP and eGFP-NleC expression levels
(Fig. 1C). TNF induction of NFB activity increased lucifer-
ase levels in control cells (6 fold) but not eGFP-NleC ex-
pressing cells (Fig. 1B). To probe the relationship of this inhi-
bition to NFB function, cells were assayed for IL-8 secretion
levels, as the IL-8 gene is under the transcriptional control of
NFB (28). Consistent with the luciferase assay data, eGFP-
expressing cells exhibited low basal levels of IL-8 secretion
with reduced levels from eGFP-NleC expressing cells (Fig.
1D). Furthermore, TNF treatment increased IL-8 secretion
levels in control cells (3-fold) but not from eGFP-NleC-
expressing cells (Fig. 1D). Thus, the nleC gene product of
EPEC has a potent capacity to inhibit NFB activity when
expressed within host cells as an N-terminally tagged eGFP
fusion protein.
NleC Inhibits NFB Function at Level of Its Constituent
Proteins—Ectopic expression of NleC inhibits basal NFB
luciferase activity by 75–80% compared with60% for the
NFB activation inhibitor (Fig. 1B versus 1A), thereby sug-
gesting that NleC inhibits signaling through multiple path-
ways. As signaling to NFB converges at the level of IKK com-
plex activation, it was predicted that NleC targets proteins at
or below the IKK complex. To examine this, HeLa cells were
co-transfected with vectors encoding (i) IKK complex compo-
nents, (ii) the luciferase reporter protein, and (iii) eGFP or
eGFP-NleC. Examination of reporter-gene expression (Fig.
2A) revealed that luciferase activity driven by plasmid expres-
sion of IKK or IKK was dramatically reduced (95%) in
pEGFP-NleC, compared with pEGFP transfected cells
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(Fig. 2A). Consistent with this finding was a similar NleC-
specific decrease in luciferase activity driven by plasmid ex-
pression of an upstream NFB pathway component; the TNF
receptor-associated factor 2 (TRAF2; Fig. 2A). Thus, the data
support the contention that NleC interferes with NFB func-
tion by targeting the IKK/ complex, or downstream com-
ponents such as IB or NFB itself. Western blot analysis
failed to detect NleC-mediated changes in the cellular level or
phosphorylation status of IKK (Fig. 2B and data not shown).
By contrast, the analysis revealed a dramatic decrease in the
cellular levels of the NFB components, p65 and p50, relative
to the actin loading control (Fig. 2B), thereby suggesting that
NleC targets the transcription factor for degradation. In sup-
port of this premise, luciferase activity induced by plasmid
expression of p65 was, in essence, abolished in pEGFP-NleC-
transfected cells (Fig. 2C).
Critical Role for NleC Residues 237–266 in Cellular Loss of
p65 and p50—Bioinformatic analyses of the 330-amino acid
residue NleC protein failed to provide clues on how it might
induce the cellular loss of NFB components. Hence, a series
of C-terminal truncations were generated in an attempt to
define regions critical for the process. Fig. 3A provides a sche-
matic of the variants used in co-transfection studies with the
NFB luciferase reporter construct. These studies confirmed
the potent inhibitory activity of full-length NleC, whereas
similar findings with the NleC1–298 and NleC1–266 variants
revealed that the C-terminal 64 residues are dispensable (Fig.
3B). However, removing another 29 (NleC1–237 variant) or
more residues (Fig. 3A) abolished the inhibitory activity of
NleC (Fig. 3B). Western blot analysis confirmed the expres-
sion of each variant (Fig. 3C) and also unlinked inhibitory de-
fects from reduced protein levels, as one of the poorest ex-
pressed proteins (pEGFP-NleC1–266) inhibited luciferase
activity nearly as effectively as NleC (Fig. 3, B and C). This
suggests that feature(s) between residues 237 and 266 are re-
quired, directly or indirectly, for the inhibitory process. How-
ever, the C-terminal NleC domain is not sufficient for the
process as an additional variant (eGFP-NleC200–330) did not
reduce luciferase reporter activity (data not shown). Probing
cellular extracts for p50, p65, and phosphorylated p65 corre-
lated the failure to inhibit luciferase activity with a defect in in-
ducing the cellular loss of these NFB components, whereas the
levels of IKK and actin control proteins remain unaffected (Fig.
3C). The partial inhibitory defect of the pEGFP-NleC1–266 vari-
ant may relate to reduced expression levels or a contributing role
of amino acid residues 267 to 298 in the inhibitory process. This
work implies that feature(s) located between residues 237 and
266 play a critical, direct or indirect, role in enabling NleC to
induce the targeted loss of NFB complex components from the
host cell.
FIGURE 1.NleC inhibits NFB-dependent protein expression and IL-8
secretion. A, relative change in NFB-dependent luciferase activity in
pEGFP (empty vector control)-transfected HeLa cells following treatment
with NFB activation inhibitor (Calbiochem product no. 481406). B, fold
increase in NFB-dependent luciferase activity. C, representative immuno-
blot showing similar expression levels of eGFP and eGFP-NleC in transfected
cells. D, IL-8 secretion levels in untreated or TNF-treated HeLa cells trans-
fected with pEGFP-NleC or pEGFP vectors. Transfection with pEGFP-NleC
inhibits luciferase activity and IL-8 secretion. Data shown are mean (S.D.)
of three experiments done in triplicate with level of significance (Student’s t
test) indicated. **, p 0.01; ***, p 0.005 as compared with empty vector
control.
FIGURE 2.NleC inhibits NFB function by targeting is constituents. Fold
increase in NFB-dependent luciferase activity of Hela cells co-transfected
with vectors encoding pEGFP or pEGFP-NleC and NFB pathway compo-
nents TRAF2, IKK, or IKK (A) and p65 (C). Transfection with pEGFP-NleC
inhibits luciferase activity associated with plasmid expression of all interro-
gated IKK pathway components. Data shown are mean (S.D.) of three
experiments done in triplicate with level of significance (Student’s t test)
indicated. ***, p 0.005 as compared with empty vector control. B, repre-
sentative immunoblot probing for actin, IKK ( and ), p65, and p50 dem-
onstrates similar levels of IKK and loading control, actin, with decreased
cellular levels of p65 and p50 in pEGFP-NleC-transfected cells.
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NleC Induces Proteasome-independent Degradation of p65
and p50—Several mechanisms have been described for regu-
lating NFB function, including proteasome-dependent deg-
radation and p65 processing by caspase and serine proteases
(7–9). To examine whether NleC is exploiting or mimicking
these processes, Western blot analyses were carried out with
antibodies against N- or C-terminal p65 domains using ex-
tracts from cells treated, or not, with the MG132 proteasome
inhibitor. This drug reduced basal NFB activity of control
and pEGFP-NleC transfected cells by50% (Fig. 4A) suggest-
ing that the NleC inhibitory process occurs independently of
the proteasomal degradation system. Moreover, the decrease
in luciferase activity implies that proteasomal degradation
antagonizes the NleC inhibitory process. Western blot analy-
sis confirmed that MG132 treatment failed to prevent NleC-
mediated cellular loss of p65 or p50 (Fig. 4B) and verified the
ability of the drug to inhibit IB degradation as it allowed
phospho-IB to accumulate within TNF-treated control
cells (Fig. 4C). Interestingly, probing for IB in extracts from
non-stimulated HeLa cells revealed its cellular loss, unlike
upstream IKK, from cells expressing eGFP-NleC, but not
eGFP or the NleC1–237 variant that does not induce cellular
loss of p50 or p65 (Fig. 4D). Thus, NleC appears to induce the
proteasome-independent loss of p50, p65, and IB. Further-
more, the inhibitory process appears to be independent of
known p65 processing events, as probing cellular extracts
with antibodies that specifically recognize the N- or C-termi-
nal domains failed to identify p65 processed forms (Fig. 4B
and data not shown). Collectively, these data suggest that
NleC targets p65, p50, and IB for proteasome-independent
degradation.
N-terminal NleC Features Are Required to Recruit NFB—
To test whether NleC interacts with NFB, GFP-Trap
beads were used to isolate eGFP, eGFP-NleC, and the eGFP-
NleC1–237 fusion protein that does not induce NFB degrada-
tion. Probing immunoprecipitates revealed that p65 and p50
interact, directly or indirectly, with NleC as they can be iso-
lated with eGFP-NleC1–237 but not eGFP (Fig. 5A). The ab-
sence of p65 or p50 from eGFP-NleC co-immunoprecipitates
(Fig. 5A) presumably reflects their rapid degradation. Thus,
features located between NleC residues 1 and 237 are in-
volved in recruiting NFB components for degradation. To
define domain(s) required in this interaction process, a series
of N-terminal truncations was generated and screened in the
luciferase reporter assay. Fig. 5B provides an illustration of the
generated variants, with screening data revealing a dispens-
able role for the first 32 residues (Fig. 5C). By contrast, features
located between residues 33 and 64 (NleC65–330) are critical
for the inhibitory process (Fig. 5C) and, thus, all remaining
variants failed to inhibit luciferase activity (data not shown).
Western blot analyses confirmed variant expression, with the
ability of eGFP-NleC33–330 but not eGFP-NleC65–330 to in-
duce the cellular loss of a NFB component illustrated (Fig.
5D and data not shown). Importantly, p65 and p50 could be
co-immunoprecipitate with the eGFP-NleC1–66 but not
eGFP-NleC65–330 variant (see Fig. 6C) revealing that N-termi-
nal features (apparently located between residues 33–64) play
a critical and sufficient role in recruiting NFB.
FIGURE 3. Key role for NleC residues 237–266 in inducing cellular loss of p65 and p50. A, schematic of NleC C-terminal truncation variants constructed
and screened in the NFB luciferase reporter assay. B, relative luciferase activity of cells expressing NleC, and variants thereof, relative to pEGFP-transfected
cells. NleC1–266, but not NleC1–237, inhibits NFB luciferase reporter activity revealing a critical role for residues between 237–266. Data shown are mean
(S.D.) of three experiments done in triplicate with level of significance (Student’s t test) indicated. *, p 0.05; ***, p 0.005 as compared with empty vec-
tor control. C, representative immunoblot probed for p65 (and phosphorylated activation-associated form; pp65), p50, IKK ( and ), actin, and GFP that
links loss of NFB luciferase reporter activity with an inability to deplete p65 and p50 from HeLa cells. aa, amino acids.
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NleC Acts as a Zinc Metalloprotease—To provide insight
into the degradation process a variety of nonspecific and spe-
cific inhibitors (including those of calpain, caspase, and auto-
phagy proteases) were screened for their ability to prevent
NleC-mediated cellular loss of p65. Importantly, only one re-
agent, a commercial inhibitor mixture (Sigma; product no.
P8340) led to the detection of NleC and p65 in the same cellu-
lar extract and hence prevented degradation (data not
shown). Interestingly, this inhibition was replicated by EDTA
as illustrated in NFB reporter luciferase assay (Fig. 6B) and
Western blot analyses (Fig. 6A), thereby indicating a key role
for a metalloprotease. Indeed, p65 and p50 could be co-im-
munoprecipitated with NleC if the cells were pretreated with
EDTA (Fig. 6C), indicating an importance for metal ions in
the degradation process. The involvement of a metallopro-
tease was supported by obtaining similar results with a metal-
loprotease-specific inhibitor, GM6001 (Fig. 6, A and B). Al-
though bioinformatics failed to reveal NleC homology to
proteases, examination of the protein sequence identified a
consensus zinc metalloprotease HEXXHmotif (29, 30) span-
ning residues 183–187 (Fig. 6D). To directly address the idea
that NleC acts as a metalloprotease that targets NFB, the
consensus motif was destroyed (Fig. 6D). NFB luciferase re-
porter activity and p65/p50 Western detection assays revealed
highly similar findings to those obtained with studies using
protease inhibitors (Fig. 6E versus Fig. 6A and Fig. 6B versus
Fig. 6F). Collectively, the work implies that NleC inhibits
NFB pathway signaling by specifically recruiting p65/p50
transcription factor complexes for degradation by its function
as a metalloprotease.
DISCUSSION
Here, it is demonstrated that the nleC gene of enteropatho-
genic E. coli encodes a protein whose expression as an eGFP-
fusion protein within HeLa cells potently inhibits the basal-
and TNF-stimulated activity of the NFB transcription
factor. This finding has applications for understanding and con-
trolling the function of this critical component of mammalian
inflammatory, immune modulation, and anti-apoptotic re-
sponses as its dysfunction is linked to inflammatory diseases
and some cancers (10, 11). Although a variety of proteins de-
livered into host cells by bacterial pathogens have been de-
scribed to inhibit NFB activity (12, 13), this study reveals
that NleC represents a novel mechanism. Thus, ectopic ex-
FIGURE 4.NleC proteasomal-independent degradation of p65, p50, and
IB. A, relative amount of NFB luciferase reporter activity in pEGFP and
pEGFP-NleC transfected cells treated, or not, with the proteasomal inhibitor
MG132 revealing that the drug reduces basal NFB activity and increases
the inhibitory activity of NleC. Data shown are mean (S.D.) of three experi-
ments done in triplicate with level of significance (Student’s t test) indi-
cated. **, p 0.01; ***, p 0.005 as compared with pEGFP-transfected cells.
B–D, representative immunoblots probing for p65, p50, IB, pIB (phosphor-
ylated form targeted for proteasomal degradation), actin, and IKK( and )
proteins in cellular extracts from cells transfected with pEGFP, pEGFP-NleC,
or pEGFP-NleC1–237 incubated, or not, with MG132. Data verify the inhibi-
tory activity of MG132 on TNF-treated cells (prevents proteasomal-depen-
dent degradation of pIB; see C) and ability of eGFP-NleC, but not eGFP or
eGFP-NleC1–237 proteins, to deplete p50, p65, and/or IB from untreated
and MG132-treated cells.
FIGURE 5. Interaction of p65 and p50 with eGFP-NleC1–237 and critical
role for NleC residues 33–64. A, representative immunoblot of anti-GFP
immunoprecipitate isolated from cells transfected with pEGFP, pEGFP-NleC,
or pEGFP-NleC1–237 probed for p65 and p50. The data reveals that p65 and
p50 can be isolated with eGFP-NleC1–237 but not eGFP or eGFP-NleC, the
latter presumably due to rapid p65/p50 degradation. B, schematic of NleC
N-terminal truncation variants constructed and screened in NFB luciferase
reporter assay. C, relative luciferase activity of cells expressing NleC and in-
dicated variants, compared with control pEGFP-transfected cells. Data
shown are mean (S.D.) of three experiments done in triplicate with level
of significance (Student’s t test) indicated. *, p 0.05; ***, p 0.005 as com-
pared with empty vector control. NleC33–330 but not NleC65–330 inhibits
NFB luciferase reporter activity revealing a critical role for residues be-
tween 33 and 64. D, representative immunoblot probed for GFP, p65, and
actin that links loss of NFB luciferase reporter activity of the NleC65–330
variants with a major defect in depleting p65 from the cell.
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pression of NleC is shown to lead to a dramatic decrease in
the cellular levels of both p65 (RelA) and p50 that comprise
the most abundant form of the dimeric transcription factor
in the canonical NFB signaling pathway (3). Although most
pathogen-encoded proteins target upstream kinases, ubiquiti-
nases, and adaptor molecules (12, 13), some target NFB
components as illustrated by chlamydia infection leading to
p65 processing, whereas another EPEC effector, NleH, binds
RPS3 to inhibit transcription of genes under the control of a
NFB-RPS3 complex (21, 31). By contrast, ectopic NleC ex-
pression induced the rapid proteasomal-independent loss of
p65 without evidence of processing intermediates. Interest-
ingly, the proteasomal inhibitor augmented NleC-mediated
inhibition of NFB activity to suggest that the effector may be
subjected to proteasomal degradation. Importantly, NleC ex-
pression also induced the cellular loss of p50 and IB, but
not the upstream pathway components IKK or IKK,
thereby demonstrating degradation specificity. IB acts to
retain NFB within the cytoplasm until IKK/-induced
phosphorylation triggers its proteasomal-dependent degrada-
tion and release of NFB for nuclear import (2). This suggests
that NleC targets NFB-IB complexes. Proteasome-inde-
pendent, not dependent, degradation of NFB components
represents a novel inhibitory mechanism.
Fluorescent microscopy studies revealed a pool of eGFP-
NleC within the nucleus, unlike the similarly sized eGFP-
NleH protein that accumulates at the cell periphery (21) (data
not shown). As NleC is significantly larger than the cut-off
size for free nuclear entry (50 kDa), this suggests that it may
carry a novel nuclear translocation signal (not evident by
bioinformatic analysis; data not shown) or enters by associat-
ing with nuclear-targeted protein(s). Of interest, the EPEC
EspF effector protein enters the nucleus by a process depen-
dent on a domain with no recognizable signal sequence (32).
Given that NleC is normally delivered into the cytoplasm and
degrades p65, p50, and IB, it is likely that its target relates
to the cytoplasmic NFB-IB complex. Given the multifunc-
tional nature of EPEC effectors (26), it is possible that nuclear
import represents a distinct function or perhaps relates to
targeting NFB-IB complexes being shuttled to the cyto-
plasm. Time course studies (epifluorescent microscopy and
Western blot analysis) have failed to resolve whether NleC
has a preference for cytoplasmic or nuclear pools of NFB
(data not shown). The mechanism and role of nuclear NleC
import in the NFB inhibitory process deserves further
investigation.
Interestingly, ectopic NleC expression inhibited the basal
NFB activity in immortalized HeLa cells to a greater extent
than the NFB activation inhibitor from Calbiochem (product
no. 481406). This suggests that this basal activity involves ad-
ditional non-canonical pathways, of which some may be sen-
sitive to NleC. It is likely that such pathways relate to other
NFB subunits composed of RelB, c-Rel, and/or p52 proteins.
Moreover, as NleC expression depletes cellular p50, this im-
plies that it would also alter the expression of genes regulated
by p50 homodimers (33). Studies are underway to define
whether NleC degrades specific isoforms of NFB (p65, RelB,
c-Rel, p105/p50, p100/p52), IB (e.g. IB, IB, IB, Bcl3),
NFB-associated cofactors (e.g. RPS3, CBP/p300) and/or co-
functional transcription factors (e.g. AP-1, STAT).
The idea, that NleC employs a novel mechanism for inhib-
iting NFB function was evidenced by the finding that loss of
transcription activity not only involves proteasome-indepen-
dent degradation of p65, p50, and IkB in the absence of p65
processing intermediates but was linked to NleC being a met-
alloprotease. The metalloprotease premise was supported by
multiple lines of evidence. First, the NFB inhibitory activity
of NleC was dramatically reduced by pretreating cells with
metalloprotease inhibitors (EDTA or GM6001) unlike chemi-
cals that interfere with caspase, calpain, or autophagosome-
related proteases. Moreover, NleC carries a consensus zinc
metalloprotease motif spanning residues 183–187 whose dis-
ruption had a similar affect as adding metalloprotease inhibi-
FIGURE 6.Metalloprotease inhibitors and disruption of the consensus
zinc metalloproteasemotif of NleC abolish p65 and p50 degradation.
A, representative immunoblot of cellular extracts from pEGFP, pEGFP-NleC,
and pEGFP-NleC transfected treated, or not, with metalloprotease inhibitors
(EDTA or GM6001). B, relative amount of NFB luciferase reporter activity for
cells described in A. C, representative immunoblot demonstrating
co-immunoprecipitating of p65 and p50 with eGFP-NleC1–66, but not eGFP-
NleC65–330, with EDTA-mediated inhibition of protease activity revealing
that full length NleC interacts with p65 and p50. The consensus zinc metal-
loprotease motif of NleC and destructive substitutions (D) with immunoblot
(E) and NFB luciferase reporter activity studies revealing the key role for
this feature in the cellular loss of p50/p65 and NFB activity (F), respectively,
are shown. Luciferase data are mean (S.D.) of three experiments done in
triplicate with level of significance (Student’s t test) indicated. ***, p 0.005
as compared with empty vector control.
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tors. A minor inhibitory activity for metalloprotease-treated
NleC and the NleC metalloprotease motif-disrupted variant
probably relates to the recruitment of NFB, directly or indi-
rectly, interfering with its transcription activity. Indeed, p65
and p50 could only be isolated with full-length NleC when it
lacked its protease function. Importantly, residues within the
first 66 residues of NleC were shown to be sufficient and es-
sential to recruit p65 and p50. Interestingly, the first 32 resi-
dues were dispensable for the inhibitory process thereby sug-
gesting that features residing between residues 33–66,
directly or indirectly, recruit canonical NFB components.
Further studies are necessary to define the residues and
mechanism (direct or indirect) by which p65, p50 and IB
are recruited to NleC for degradation. The requirement for
residues 237–266 (upstream of the zinc metalloprotease mo-
tif) but not residues 267–330 in the inhibitory process pre-
sumably reflects an indirect deleterious consequence on a
NleC protein structure needed for its protease activity. Col-
lectively, the data is consistent with a model (see Fig. 7)
whereby NleC, directly or indirectly, interacts with NFB-
IB complexes via features residing between residues 33 and
64 for degradation though its function as a zinc
metalloprotease.
Little is known about the role of NleC in the context of
pathogenesis, as deleting the nleC gene does not impact on
virulence, at least in interrogated strains and models (34, 35).
Studies using a disease-relevant small intestinal model suggest
that NFB cellular levels remain relatively unchanged follow-
ing EPEC infections where NFB function has been inhibited
(25). Recent work suggests that such inhibition is due to the
activity of the NleB and NleE effectors predicted to act at the
level of IKK or the upstream kinase TGF--activated kinase 1
(19, 20). Nevertheless, these studies are consistent with con-
tributions for other effectors, a premise illustrated by the doc-
umented role for NleH (21). Although EPEC can deliver plas-
mid-expressed NleC into host cells, an interrogated EPEC
strain displayed little evidence of native nleC gene transcrip-
tion or NleC production under the examined conditions (36).
Preliminary studies support EPEC delivery of plasmid-ex-
pressed NleC in host cells where it decreases cellular levels of
p65 and p50 (data not shown). Why EPEC have evolved
mechanisms to limit the level of NleC within host cells and/or
the ability of the effectors to degrade NFB remains to be de-
fined. Despite the apparent subtle role for NleC in inhibiting
NFB function within the context of an infection, the protein
has a potent NFB-specific degradation activity that may be
useful for inhibiting the function of this transcriptional factor
whose dysfunction is linked to inflammatory diseases and
some cancers (10, 11). Thus, the novel NFB-specific protease
property of NleC has interesting applications. Firstly, as pro-
teins (such as the120-kDa functionally active -galactosi-
dase) can be delivered into cells in culture and whole animal
models (37), NleC may be useful not only as a NFB research
tool but also in validating NFB as a therapeutic target in dis-
ease samples or, indeed, as a therapeutic reagent.
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